These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34823736)

  • 1. Understanding Stimulant Use and Use Disorders in a New Era.
    Ciccarone D; Shoptaw S
    Med Clin North Am; 2022 Jan; 106(1):81-97. PubMed ID: 34823736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis.
    Ciccarone D
    Curr Opin Psychiatry; 2021 Jul; 34(4):344-350. PubMed ID: 33965972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methamphetamine Use: A New Wave in the Opioid Crisis?
    Fogger SA
    J Addict Nurs; 2019; 30(3):219-223. PubMed ID: 31478970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021.
    Friedman J; Shover CL
    Addiction; 2023 Dec; 118(12):2477-2485. PubMed ID: 37705148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving.
    Ahmadi J; Sahraian A; Biuseh M
    Trials; 2019 Jul; 20(1):468. PubMed ID: 31362784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy.
    Ciccarone D
    Prim Care; 2011 Mar; 38(1):41-58. PubMed ID: 21356420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry.
    Fredericksen RJ; Baker R; Sibley A; Estadt AT; Colston D; Mixson LS; Walters S; Bresett J; Levander XA; Leichtling G; Davy-Mendez T; Powell M; Stopka TJ; Pho M; Feinberg J; Ezell J; Zule W; Seal D; Cooper HLF; Whitney BM; Delaney JAC; Crane HM; Tsui JI
    Harm Reduct J; 2024 Apr; 21(1):74. PubMed ID: 38561753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence and Pervasiveness : Early Wave Opioid Overdose Death Rates Associated With Subsequent Overdose Death Rates.
    Segel JE; Winkelman TNA
    Public Health Rep; 2021; 136(2):212-218. PubMed ID: 33301695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current data on methamphetamine].
    Cottencin O; Rolland B; Guardia D; Karila L
    Rev Prat; 2012 May; 62(5):679-81. PubMed ID: 22730802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences.
    Davidson C; Lee TH; Ellinwood EH
    Neurochem Int; 2005 Feb; 46(3):189-203. PubMed ID: 15670635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anhedonia and amotivation in psychiatric outpatients with fully remitted stimulant use disorder.
    Leventhal AM; Kahler CW; Ray LA; Stone K; Young D; Chelminski I; Zimmerman M
    Am J Addict; 2008; 17(3):218-23. PubMed ID: 18463999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.
    Kishi T; Matsuda Y; Iwata N; Correll CU
    J Clin Psychiatry; 2013 Dec; 74(12):e1169-80. PubMed ID: 24434105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Stimulant Selective Severity Assessment: A replication and exploratory extension of the Cocaine Selective Severity Assessment.
    Walker R; Northrup TF; Tillitski J; Bernstein I; Greer TL; Trivedi MH
    Subst Use Misuse; 2019; 54(3):351-361. PubMed ID: 30657406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women.
    Smid MC; Metz TD; Gordon AJ
    Clin Obstet Gynecol; 2019 Mar; 62(1):168-184. PubMed ID: 30601144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.
    Jordan CJ; Cao J; Newman AH; Xi ZX
    Neuropharmacology; 2019 Nov; 158():107609. PubMed ID: 31009632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical management of psychostimulant withdrawal: review of the evidence.
    Li MJ; Shoptaw SJ
    Addiction; 2023 Apr; 118(4):750-762. PubMed ID: 36401591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effects and management of methamphetamine abuse.
    Romanelli F; Smith KM
    Pharmacotherapy; 2006 Aug; 26(8):1148-56. PubMed ID: 16863490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between prescription and illicit stimulant and opioid use in the United States, 2015-2020.
    Shearer RD; Jones A; Howell BA; Segel JE; Winkelman TNA
    J Subst Abuse Treat; 2022 Dec; 143():108894. PubMed ID: 36206585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.
    Poling J; Oliveto A; Petry N; Sofuoglu M; Gonsai K; Gonzalez G; Martell B; Kosten TR
    Arch Gen Psychiatry; 2006 Feb; 63(2):219-28. PubMed ID: 16461866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.
    Cruickshank CC; Montebello ME; Dyer KR; Quigley A; Blaszczyk J; Tomkins S; Shand D
    Drug Alcohol Rev; 2008 May; 27(3):326-33. PubMed ID: 18368615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.